Impact of anemia on major bleeding in patients taking oral anticoagulants for nonvalvular atrial fibrillation.
anemia
atrial fibrillation
bleeding
oral anticoagulants
registry
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
22
03
2023
revised:
26
05
2023
accepted:
05
06
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Anemia is encountered in patients with nonvalvular atrial fibrillation (NVAF) on oral anticoagulants (OACs) but the prognostic impact was not well scrutinized in real-world settings. We conducted a historical multicenter registry of patients with NVAF taking OACs at 71 centers in Japan. Those with mechanical heart valves or a history of pulmonary thrombosis or deep venous thrombosis were excluded. Anemic patients were divided into three groups of hemoglobin (Hb) level: moderate/severe (Hb < 11.0 g/dL), mild (men: Hb of 11.0-12.9 g/dL; women: Hb of 11.0-11.9 g/dL), and no anemia. The endpoints included major bleeding, hemorrhagic stroke, ischemic events, ischemic stroke, and all-cause mortality. Among 7558 consecutive patients (mean age, 73 years; men 67%) registered in February 2013 and followed until February 2017, 2100 (28%) patients had anemia. The anemic patients were older (moderate/severe: 79 years; mild: 77 years; no anemia: 71 years, The severity of anemia in the patients with NVAF on OACs was associated with major bleeding.
Sections du résumé
Background
UNASSIGNED
Anemia is encountered in patients with nonvalvular atrial fibrillation (NVAF) on oral anticoagulants (OACs) but the prognostic impact was not well scrutinized in real-world settings.
Methods
UNASSIGNED
We conducted a historical multicenter registry of patients with NVAF taking OACs at 71 centers in Japan. Those with mechanical heart valves or a history of pulmonary thrombosis or deep venous thrombosis were excluded. Anemic patients were divided into three groups of hemoglobin (Hb) level: moderate/severe (Hb < 11.0 g/dL), mild (men: Hb of 11.0-12.9 g/dL; women: Hb of 11.0-11.9 g/dL), and no anemia. The endpoints included major bleeding, hemorrhagic stroke, ischemic events, ischemic stroke, and all-cause mortality.
Results
UNASSIGNED
Among 7558 consecutive patients (mean age, 73 years; men 67%) registered in February 2013 and followed until February 2017, 2100 (28%) patients had anemia. The anemic patients were older (moderate/severe: 79 years; mild: 77 years; no anemia: 71 years,
Conclusions
UNASSIGNED
The severity of anemia in the patients with NVAF on OACs was associated with major bleeding.
Identifiants
pubmed: 37560265
doi: 10.1002/joa3.12885
pii: JOA312885
pmc: PMC10407181
doi:
Types de publication
Journal Article
Langues
eng
Pagination
556-565Informations de copyright
© 2023 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
Dr. Kinjo, Dr. Sakakibara, Dr. Nezu, and Dr. Arai have no disclosures to report. Dr. Uchida reports lecturer's fees from Daiichi Sankyo. Dr. Ueda reports receiving a research grant from Bristol‐Myers Squibb, Chugai, Kowa, MSD, Pfizer, and Takeda, lecturer's fee from Boehringer Ingelheim, MSD, and Taiho, and manuscript fees from Kowa. He served on an advisory board for Otsuka. Dr. Morimoto reports lecturer's fees from Bayer, Daiichi Sankyo, Japan Lifeline, Kyocera, Mitsubishi Tanabe, Novartis, and Toray; the manuscript fees from Bristol‐Myers Squibb and Kowa; served advisory boards for Asahi Kasei, Boston Scientific, Bristol‐Myers Squibb, and Sanofi.
Références
J Am Coll Cardiol. 2015 Jul 28;66(4):403-69
pubmed: 25553722
N Engl J Med. 2017 Nov 30;377(22):2133-2144
pubmed: 29130845
Eur Heart J. 2007 Aug;28(16):1936-45
pubmed: 17575270
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
J Thromb Thrombolysis. 2018 Apr;45(3):360-368
pubmed: 29383557
Arch Neurol. 1976 Mar;33(3):206-14
pubmed: 1252166
J Thromb Thrombolysis. 2019 Apr;47(3):444-453
pubmed: 30673941
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Am Heart J. 2017 Mar;185:140-149
pubmed: 28267467
World Health Organ Tech Rep Ser. 1968;405:5-37
pubmed: 4975372
JACC Cardiovasc Interv. 2015 Mar;8(3):436-446
pubmed: 25703883
JAMA. 2017 Oct 3;318(13):1250-1259
pubmed: 28973247
Am J Cardiovasc Drugs. 2023 Jan;23(1):89-99
pubmed: 36380115
Neurology. 2014 Sep 23;83(13):1220
pubmed: 25253878
Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1321-1331
pubmed: 33715291
Clin Interv Aging. 2014 Jul 22;9:1187-96
pubmed: 25092968
Am J Cardiol. 2018 Aug 1;122(3):388-394
pubmed: 29961563
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607